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Introduction: Increased expression of thymidylate synthase (TS) is 
thought to be associated with resistance to TS-targeting drugs, e.g., 
pemetrexed.
Methods: TS protein expression (PE) and gene copy number (GCN) 
were assayed using immunohistochemistry and silver in situ hybrid-
ization, respectively, on primary tumors of 189 resected non–small cell 
lung patients. Associations with pathological and clinical features 
and prognosis were explored.
Results: Median immunohistochemistry H-score was 220 (range, 
10–380) on a 0 to 400 scale; 17% of the patients had a TS expres-
sion of 300 or more. TS PE expression did not significantly differ 
by histology and did not significantly associate with disease-free 
survival (DFS) or overall survival (oS). However, there was a ten-
dency for increased DFS (p  0.12) and oS (p  0.12) in PE positive 
(median) squamous-cell carcinoma (SCC) patients. Median GCN 
was 2.5 genes/nucleus (range, 1.4–9.6); 29% of patients had GCN of 
3 or more, 7% of 4 or more and 0.8% amplification. GCN differed by 
histology (p  0.015); 50% of SCCs having GCN more than 2.5 ver-
sus 32% of adenocarcinomas. There was no significant relationship 
between TS GCN and DFS or oS; however, a trend toward better 
DFS (p  0.18) and oS (p  0.10) with increased GCN in SCCs was 
observed. TS GCN was significantly correlated with PE (r  0.30, 
p  0.0009).
Conclusions: TS PE and GCN vary widely in non–small cell lung and 
correlate significantly with each other. TS GCN is higher in SCCs, 
whereas TS PE does not associate with histological subtypes, clini-
cal features, or survival. Variability of TS PE and GCN may indicate 
potential benefit from pemetrexed therapy in selected SCC patients.
Key Words: Thymidylate synthase, Biomarker, Protein expression, 
Gene copy number, Immunohistochemistry, In situ hybridization, 
Lung cancer, Prognosis, Pemetrexed.
(J Thorac Oncol. 2012;7: 982–992)
Lung cancer is the leading cause of cancer-related mortality worldwide, causing more than one million deaths annually. 
Despite advances in surgical techniques, radiation, and sys-
temic treatments, prognosis is still very poor, with cure rates 
around 15%.1,2
A promising approach to improve outcomes is the 
customization of chemotherapy according to individual phe-
notype of the tumor, including its histology or molecular 
features. Pemetrexed is a cytotoxic agent that targets at least 
three folate-dependent enzymes, thymidylate synthase (TS), 
dihydrofolate reductase, and glycinamide ribonucleotidyl 
formyl transferase.3,4 In the landmark phase-III randomized 
trial chemonaïve patients with advanced nonsquamous lung 
cancer (non-SCC) had improved survival following cispla-
tin and pemetrexed compared to cisplatin and gemcitabine 
(median of 11.8 versus 10.4 months; hazard ratio [HR]  
0.81; p 0.005), whereas the opposite was true in patients 
with SCC (median of 9.4 versus 10.8 months; HR  1.23; 
p  0.05).5 Likewise, a randomized phase-III study examin-
ing maintenance pemetrexed versus best supportive care fol-
lowing four cycles of platinum-based chemotherapy showed 
improved survival with pemetrexed in patients with non-SCC 
histology (HR 0.70; p  0.002), but not in patients with 
SCC (HR 1.07; p  0.678).6 In consequence, pemetrexed is 
currently approved in patients with advanced non-SCCs as 
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first-line, second-line, and maintenance therapy. However, 
although histology is the labeled indication for pemetrexed 
therapy in non–small cell lung (NSCLC), more specific 
molecular markers could potentially give a better prediction 
for sensitivity or resistance to this agent.
The higher efficacy of pemetrexed in non-SCC ver-
sus that in SCC is believed to be attributed to differential 
expression of TS, the main inhibitory target of this agent. 
In a study involving early-stage NSCLC patients (n  56), 
TS mRNA and protein levels were significantly lower in the 
samples of adenocarcinoma (ADC) compared to SCC.7 In 
a study including 11 NSCLC cell lines, resistance to pem-
etrexed was significantly associated with increasing TS gene 
expression.8 In a phase-II clinical trial evaluating a combi-
nation of gemcitabine and pemetrexed in stage-IB through 
III-NSCLC patients, tumor response was inversely associ-
ated with TS expression.9 TS gene copy number (GCN) gain 
evaluated by ooyama et al.10 seems to be associated with 
resistance to antifolates. Amplification of TS gene, as deter-
mined by polymerase chain reaction (PCR), was shown to 
better predict outcome than protein expression (PE) assessed 
by immunohistochemistry (IHC).11 Thus, TS seems to be 
a strong candidate as a predictive marker for pemetrexed 
sensitivity/resistance, but the optimal assay method remains 
to be established.
The aims of our study were to profile surgically resected 
NSCLC for TS PE using IHC and for TS GCN using a new 
technique, silver in situ hybridization (SISH). Both assays 
are easily applied clinically and may potentially serve as pre-
dictive assays for pemetrexed therapy. We specifically aimed 
to determine a correlation between the two variables and 
associations with pathological and clinical features includ-
ing histology, disease-free survival (DFS) and overall sur-
vival (oS).
PATIENTS AND METHODS
Patient Population
Primary tumor samples were obtained from 189 con-
secutive NSCLC patients initially clinically staged I through 
III (Union for International Cancer Control, tumor, node, 
metastasis classification of malignant tumors, 6th edition) 
who underwent curative pulmonary resection at the Medical 
University of Gdansk, Poland between 2001 and 2004 (Table 1). 
Histological classification was verified according to World 
TABLE 1. TS Protein Expression and Gene Copy Number versus Patient Characteristics
Total Population TS Protein Expression TS Gene Copy Number
Characteristics 220 220 p value 2.50 2.50 p value
n 189 89 79 64 60
Age, yrs
 Mean (SD) 63 (9) 61 (9) 65 (6) 0.013 64 (8) 62 (9) 0.147
 60, n (%) 118 (62) 41 (46) 21 (27) 0.011 16 (25) 26 (43) 0.038
 60, n (%) 71 (38) 48 (54) 58 (73) 48 (75) 34 (57)
Sex, n (%)
 Female 45 (24) 20 (22) 17 (22) 0.999 10 (16) 11 (18) 0.812
 Male 144 (76) 69 (78) 62 (78) 54 (84) 49 (82)
Smoking Status, n (%)
 Ever 180 (95) 82 (92) 78 (99) 0.068 60 (94) 0 (0) 0.120
 Never 9 (5) 7 (8) 1 (1) 4 (6) 60 (100)
Histology, n (%)
 AC 55 (29) 26 (29) 21 (27) 21 (33) 10 (17)
 SCC 103 (55) 54 (61) 40 (51) 37 (58) 37 (62)
 LCC 5 (3) 1 (1) 4 (5) 0.168 2 (3) 1 (2) 0.015
 NoS/Mixed 24 (13) 8 (9) 12 (15) 3 (5) 12 (20)
 Missing 2 (1) 0 (0) 2 (2) 1 (2) 0(0)
Pathological Stage, n (%)
 I 75 (40) 31 (35) 33 (42) 22 (34) 26 (43)
 II 42 (22) 25 (28) 15 (19) 0.372 14 (22) 17 (28) 0.277
 III/IV 69 (36) 32 (36) 29 (37) 27 (42) 17 (28)
 Missing 3 (2) 1 (1) 2 (2) 1 (2) 0 (0)
Grade, n (%)
 G1 20 (11) 10 (11) 8 (10) 9 (14) 9 (15)
 G2 81 (43) 43 (48) 28 (35) 0.245 31 (48) 19 (32) 0.174
 G3 63 (33) 25 (28) 30 (38) 16 (25) 22 (37)
 Missing 25 (13) 11 (12) 13 (17) 8 (13) 10 (17)
TS, thymidylate synthase; AC, adenocarcinoma; SCC, squamous-cell carcinoma; LCC, large-cell carcinoma; NoS, not otherwise specified.
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Health organization 2004 criteria by a board-certified patholo-
gist. Because positron emission tomography was not available 
during the collection period, a few patients were upstaged at 
surgery, thus resulting in a portion of patients with pathological 
stage III (32%) and stage IV (4%), all of which were included 
in this study. Induction or adjuvant chemotherapy was used in 
a small fraction of patients (4% and 2%, respectively), as those 
treatments were not routinely used per institutional guidelines 
in the period of this study. DFS was calculated from the date 
of surgery to the date of relapse (distant or local), death by any 
cause or last follow-up. oS was defined as the time between sur-
gery and death by any cause or last follow-up. Median follow-up 
was 5.3 years (range, 1.1–6.9 years). Institutional review boards 
from both the Medical University of Gdansk and the University 
of Colorado approved research conduct for this study.
Tissue Microarray Preparation
Tissue microarrays (TMA) were prepared as described 
previously.12 Briefly, three 1.5 mm diameter cores were 
obtained manually from representative tumor areas from each 
formalin-fixed paraffin-embedded tumor block. These cores 
were taken from different areas with different tumor differ-
entiation patterns if heterogeneity was present. Therefore, it 
is unlikely that the choice of a particular histological pattern 
for core selection biases the results of this analysis. Tissue 
cores were processed using MaxArray customized TMA ser-
vice (Invitrogen, South San Francisco, CA). Sections of 4 m 
were cut from TMA master blocks, mounted on slides and 
processed as described below.
TS Protein Expression
TS PE was evaluated using automated IHC on the 
BenchMark XT autostainer (Ventana Medical Systems, Inc., 
Tucson, AZ). Tissue sections were heated in a 60°C dry oven 
for 1 hour before transfer to the autostainer where they were 
then treated with cell-conditioning solution 1 for 1 hour. The 
TS primary antibody (4H4B1, Invitrogen, Carlsbad, CA) 
was added manually at a 1:10 dilution and incubated for 1 
hour at 25°C. The Ultra View (Ventana Medical Systems, 
Inc, Tucson, AZ) diamino benzidine detection kit was used 
in conjunction with the amplification kit. After washing, the 
slides were counterstained with hematoxylin for 4 minutes. 
The slides were removed from the autostainer and washed 
with mild soapy water, and dehydrated in a graded series of 
ethyl-alcohol baths and xylene baths. Positive (colon carci-
noma) and negative (colon carcinoma with nonimmune IgG as 
primary antibody) controls were included in all series. A cer-
tified pathologist (B.R.A.) scored the slides using the hybrid 
(H) scoring method: H-score  % cells of 0 intensity + (% 
cells of 1 intensity  1)  (% cells of 2  intensity  2)  
(% cells of 3  intensity  3)  (% cell of 4  intensity  4). 
The intensity score was defined as: 0, no appreciable staining 
in the tumor cells, 1+, barely detectable staining in the cyto-
plasm and/or nucleus compared with the stromal elements, 
2, readily appreciable brown staining distinctly marking the 
tumor cell cytoplasm and/or nucleus, 3, dark brown staining 
in tumor cells obscuring the cytoplasm and/or nucleus, and 
4, very strong dark staining (Fig. 1).
TS Gene Copy Number
TS GCN was assayed using automated SISH on the 
BenchMark XT autostainer (Ventana Medical Systems, Inc., 
Tucson, AZ). The dinitrophenol labeled TS DNA repeat-free 
probe, generously provided by Ventana Medical Systems, Inc., 
is designed against a 1-Mb amplicon on 18p11.32, and opti-
mally formulated for use with the UltraView SISH Detection 
Kit and accessory reagents. The TMA was probed accord-
ing to the manufacturer’s instructions. Briefly, the TS probe 
was denatured at 95°C for 12 minutes and hybridization was 
performed at 52°C for 4 hours. Hybridization was followed 
by three stringency washes at 72°C. The probe was visual-
ized using a rabbit anti-dinitrophenyl primary antibody and a 
detection kit containing a goat anti-rabbit secondary antibody 
conjugated with horseradish peroxidase. The sequential addi-
tion of silver A (silver acetate), silver B (hydroquinone), and 
silver C (hydrogen peroxide) resulted in the silver ions being 
reduced by hydroquinone to metallic silver atoms as a conse-
quence of horseradish peroxidase oxidation of hydrogen per-
oxide. The silver precipitate was deposited in the nuclei, and a 
single copy of the TS gene was visualized as a single discrete 
FIGURE 1. Representative photomicrographs of the varying 
range of TS protein expression detected by IHC. A, H-score 
of 70, (B), H-score of 150, (C), H-score of 210, (D) H-score of 
280, and (E) H-score of 355. TS, thymidylate synthase; IHC, 
immunohistochemistry.
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black dot, whereas a tight cluster of black dots stacked so 
closely together that individual signals could not be resolved 
were considered amplified TS genes. The slide was then coun-
terstained with hematoxilin II and bluing reagent. All tumor 
specimens were visualized with brightfield microscopy, evalu-
ated for tumor adequacy, and scored by a certified pathologist 
(SS). SISH-detection system allows the observer to simultane-
ously examine TS GCN and the tumor nuclei morphology, and 
count GCN only within tumor nuclei (Fig. 2). Signals were 
counted by scanning the entire core and focusing on regions 
that seemed to have the highest copy numbers. Fifty nonover-
lapping nuclei were counted, less if the TMA core was par-
tially depleted, with a minimum of 20 tumor cells required for 
analysis. Individual signals were given a score of one, small 
clusters a score of six, and big clusters a score of 12, simi-
larly to published reports for HER2 GCN evaluation in breast 
cancer.13 The scores were analyzed to determine the mean TS 
GCN per nucleus per core.
Statistical Analysis
Pearson’s correlation coefficient was used to assess cor-
relation between continuous variables. Associations between 
categorical variables were explored using Fisher’s exact test. 
Survival curves were plotted using the Kaplan-Meier method 
and compared by log-rank test. Cox proportional hazard mod-
els were used for multivariate comparisons. All reported p val-
ues were two-sided with a significance level of 0.05, with no 
adjustment made for multiple comparisons.
RESULTS
TS Protein Expression
TS PE was evaluable in 168 of the 189 patient specimens 
(89%) on the TMA with the most common cause for nonevalu-
ability being depleted tissue, followed by lack of tumor tissue 
within the specimen. No statistically significant difference in the 
distribution of patient characteristics was observed between the 
TS IHC evaluable and nonevaluable cases. The average H-score 
of the triplicate cores per patient was highly correlated to the 
core with the highest score from the same patient (Pearson’s 
correlation coefficient 0.97), and therefore further analyses were 
performed using the maximum H-score. For the entire evalu-
able population the PE level of TS ranged from a H-score of 10 
to 380 with a median of 220, a mean of 219 with a SD of  75 
(Fig. 3A). Tumors from 29 patients (17%) had very high (300) 
expression of TS. The distribution of TS expression was simi-
lar in ADCs (median, 220; range, 10–350; mean, 212,; SD 77) 
and squamous-cell carcinomas (median, 210; range, 50–380; 
mea,. 213; SD, 72) (Fig. 3B and 3C). A group including large-
cell carcinomas and not otherwise specified (NoS) carcinomas 
tended to have higher values, with a median of 280 (115–365) 
and mean of 256 73 (Fig. 3D).
Patients with high TS PE were 3.5 years older on aver-
age and were 20% more likely to be more than 60 years of 
age (Table 1). No significant associations were found with the 
other clinical features: sex, histology, stage, grade, and smok-
ing status.
The relationship between TS PE and DFS and oS was 
evaluated using an H-score of 220, the median for the popula-
tion, as the cutoff point. Ten patients with an exact H-score of 
220 were assigned to the 220 or less group (n  89) patients, 
and the remaining 79 patients had an H-score of more than 220. 
There was no association between TS PE and either DFS (log-
rank p  0.26) or oS (log-rank p  0.38) in the entire series 
(Fig. 4A and 4B). Similarly, when examining PE as a continu-
ous variable and adjusting for age, sex, smoking, stage, and 
grade, there was no relationship between TS and either DFS 
(HR 1.00 p  0.36) or oS (HR 1.00 p  0.37). However, in 
patients with SCC histology, although it was not statistically 
different, there was a tendency for improved DFS (log-rank 
p  0.12) and oS (log-rank p  0.12) in those who expressed 
higher levels of TS protein in the tumors (Fig. 4C and 4D). 
The median DFS for those with high and low TS expression 
was 1.7 years and 1.1 years, respectively, and the median oS 
in both groups was 2.8 years versus 1.5 years, respectively. 
There was no prognostic impact of TS PE for either DFS 
(log-rank p  0.77) or oS (log-rank p  0.54) in patients with 
nonsquamous NSCLC (Fig. 4E and 4F).
We also retrospectively combined the 4+ intensity cat-
egory with the 3+ category and recalculated the H-scores. The 
FIGURE 2. Representative photomicrographs of TS gene 
copy number detected by SISH. A, 1.8 genes per nucleus, (B), 
3.2 genes per nucleus, (C), 3.7 genes per nucleus, (D), 5.0 
genes per nucleus, and (E) 9.6 genes per nucleus. TS, thymi-
dylate synthase; SISH, silver in situ hybridization.
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new median was 210 instead of 220, and 76 of the 79 patients 
that were in the positive group using the 0 to 400 scale were 
also in the positive group using the 0 to 300 scale. The three 
who were no longer positive on the 0 to 300 scale had a score 
of 210 (new median), but because the cutpoint was more than 
210 they moved to the negative group. only one patient, of 89, 
who was part of the negative group (0–400 scale) was added to 
the positive group (0–300 scale). The H-score for this patient 
was 220 using both scales. There was still no difference in 
the overall PE between histological subtypes (p  0.29) and 
no association with DFS (log-rank p  0.38) or oS (log-rank 
p  0.51) when 3+ and 4+ were combined and the new median 
(210) was evaluated; in fact, there was less separation of the 
curves (data not shown).
TS Gene Copy Number
TS GCN was evaluable in 124 of the 189 patient speci-
mens (66%) on the TMA; the remaining nondepleted samples 
had insufficient signals or inadequate tumor cell number for 
the analysis. The evaluable population was representative of 
the entire cohort of NSCLC patients and there was no statisti-
cal difference between the two subsets. The average GCN of 
the triplicate cores per tumor was compared to the maximum 
core of the same tumor. The highest scored core was used for 
further analyses because of exceptional correlation between 
the two (r  0.97). In the entire evaluable NSCLC population 
TS GCN ranged widely from 1.4 to 9.6 genes per nucleus (Fig. 
5A), with a median of 2.5 genes per nucleus and a mean of 2.7 
(SD  1.0). Tumors from 36 patients (29%) had a GCN of 3 or 
more genes per nucleus, 9 (7%) had a GCN of 4 or more, and 
one (0.8%) had true gene amplification (Fig. 2E).
In the 31 evaluable ADCs the median and mean TS GCN 
were 2.2 (range, 1.6–4.5) and 2.4 (SD  0.7), respectively 
(Fig. 5B). Six ADCs showed a GCN of three or more, two had 
GCN of four or more, but there was no gene amplification. 
Median and mean TS GCN in the 74 SCCs was 2.5 (range, 
1.4–9.6) and 2.8 (SD  1.2), respectively (Fig. 5C). Twenty-
three SCCs had three or more genes per nucleus, seven had a 
GCN of four or more, and one had gene amplification. In the 
subset of large-cell carcinoma and NoS cancers (n  19) the 
median and mean TS GCNs were 2.9 (range, 1.5–3.4) and 2.8 
(SD  0.6), respectively (Fig. 5D). There were no samples 
with four or more TS gene copies, seven tumors had three or 
more copies, and none had gene amplification in this subset 
of histologies.
TS GCN significantly differed by histology (p  0.015). 
TS GCN more than 2.5 genes per nucleus, the median of the 
entire evaluable population, was found in 10 of 31 ADCs, 37 
of 74 SCCs, and 13 of 19 of the combined large-cell carcinoma 
and NoS histologies (Table 1). In addition, TS GCN was higher 
FIGURE 3. Histograms showing the distribution, frequency, median, range, mean, and SD for TS protein expression in NSCLC. 
(A), entire evaluable population, (B), adenocarcinoma, (C), squamous-cell carcinoma, (D) large-cell carcinoma or not otherwise 
specified histology. TS, thymidylate synthase; NSCLC, non-small cell lung cancer.
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in tumors from patients younger than 60 years (p = 0.038). No 
associations were found with any of the other clinical features 
examined: sex, smoking status, stage, or grade.
In the univariate analysis of all patients using the 
median GCN for the population (2.5 genes per nucleus) as the 
cutpoint, the TS GCN was not associated with DFS (log-rank 
p  0.28) (Fig. 6A) or oS (log-rank p  0.40) (Fig. 6B). Three 
cases with 2.5 genes per nucleus were assigned to the group of 
GCN of 2.5 or less (n  64), and the remaining 60 cases had 
GCN of more than 2.5. Likewise, no differences were found 
when TS GCN was considered as a continuous variable and 
after adjustment for age, sex, smoking status, histology, stage, 
and grade: the HRs for DFS and oS were 0.96 (p  0.77) and 
0.94 (p  0.70), respectively. In the SCC subset, similar to 
the PE findings, there was no significant difference but a ten-
dency for association between high GCN and increased DFS 
FIGURE 4. Kaplan-Meier survival probability curves. Disease-free survival (A) and overall survival (B) according to 
TS protein expression for the entire evaluable population stratified at the median (H-score 220). Disease-free survival  
(C and E) and overall survival (D and F) for those with squamous-cell carcinoma and nonsquamous carcinoma, respectively, 
stratified at H-score 220. TS, thymidylate synthase.
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(log-rank p  0.18) (Fig. 6C) and oS (log-rank p  0.10) 
(Fig. 6D). Although these associations were not significant, the 
median DFS was 1.8 years versus 1.4 years, and the median 
oS was 4.0 years versus 1.5 years for high versus low GCN, 
respectively. No such associations were found for non-SCCs 
(log-rank for progression-free survival and oS p  0.68 and 
p  0.55, respectively) (Fig. 6E and 6F).
Relationship Between TS PE and GCN
The relationship between TS PE and GCN was exam-
ined in the 119 patients for whom both values were available. 
There was a significant correlation (Pearson’s r  0.30, p  
0.0009) between the TS H-score and GCN (Fig. 7). This popu-
lation had one patient with very high GCN and when this out-
lier was excluded from the analysis, the correlation coefficient 
increased to r  0.38, p  0.0001. In the combined analysis 
including both TS PE and GCN, DFS tended to be positively 
associated with increased PE and GCN (median 5.1 years 
versus 1.3 years; log-rank p  0.11) and oS (median oS not 
reached versus 1.3 years, log-rank p  0.05; data not shown).
DISCUSSION
To our knowledge, this study is the first report on TS 
PE analyzed and compared to TS GCN in the primary tumors 
from a large consecutive series of surgically treated NSCLC 
patients. We demonstrated a similar distribution of TS PE 
in tumors with SCC and ADC histology, but higher GCN 
by SISH in SCC, although, there was a great variability in 
this subtype of NSCLC. Neither the TS PE nor the GCN 
correlated significantly to the prognosis. Furthermore, this 
study is the first to evaluate the SISH as a new method for 
TS GCN, and this study also demonstrated this assay as 
having easy clinical application. The technology is today 
used for HER2 GCN assessment,14 and TS SISH could be a 
potential assay for the prediction of response and outcome 
to pemetrexed.
The lack of TS PE association with histology in our 
study is in contrast with some other published data showing 
higher TS PE in SCCs as compared with ADCs.7 However, 
similar to our findings, one study using automated quantitative 
fluorescence microscopy found no association to histology for 
TS PE levels,15 and another study using IHC likewise found no 
statistical association.16 Association with histology has been 
documented for TS mRNA level7,17 and, taken together with 
in vitro data,18 has provided the hypothesis for higher pem-
etrexed efficacy in patients with ADCs because of lower levels 
of TS expression. However, these aforementioned studies also 
showed that a proportion of SCCs have low TS protein level, 
similar to our findings.
FIGURE 5. Histograms showing the distribution, frequency, median, range, mean, SD and amplification for TS gene copy 
number in NSCLC. A, the entire evaluable population, (B), those with adenocarcinoma, (C), squamous-cell carcinoma, or (D), 
large-cell carcinoma or not otherwise specified histology. TS, thymidylate synthase; NSCLC, non–small cell lung cancer.
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our study found no association between TS PE and DFS 
or oS in the analysis of the whole population. However, for 
patients with SCC histology, there was a separation of the sur-
vival curves and a trend for improved DFS and oS with higher 
TS PE, which may reach statistical significance in a larger 
cohort. The prognostic significance of TS PE in operable 
NSCLC patients remains debatable. one study showed a posi-
tive prognostic impact of high TS PE determined by automated 
quantitative fluorescence microscopy, when stratified at the 25 
percentile.15 However, in that study, the TS PE was not associ-
ated with oS when dichotomized at the median. other stud-
ies focusing exclusively on ADC in Japanese patients showed 
association between high TS PE and high proliferative indices, 
and adverse impact of this feature on prognosis.16,19–21 Shintani 
et al.22 showed that, whereas low TS mRNA associated with 
improved DFS, there was no association between DFS and PE. 
FIGURE 6. Kaplan-Meier survival probability curves. Disease-free survival (A) and overall survival (B) according to TS GCN for 
the entire evaluable population stratified at the median (GCN 2.5). Disease-free survival (C and E) and overall survival (D and 
F) for those with squamous-cell carcinoma and nonsquamous carcinoma, respectively, stratified at GCN 2.5. TS, thymidylate 
synthase; GCN, gene copy number.
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Inconsistent results of the mentioned studies may be attributed 
to prognostic differences of TS PE according to histology or 
ethnicity, differences in clinical cohort characteristics, and/or 
lack of standardized assay methods and data analysis. We can-
not definitively explain our finding of a nonsignificant trend 
for better outcome of the subset of SCC patients with higher 
TS levels. This finding may be of chance alone. It is also pos-
sible that the biological significance of TS is of less impor-
tance for tumor proliferation and prognosis than that of other 
molecular events, such as protein overexpression and/or the 
gene amplification of other genes.
We quantified our PE using the previously published 
H-score method on a 0 to 400 scale,12,23–30 whereas other stud-
ies with other markers have used the range of 0 to 300.31 We are 
well aware of the potential differences between 0 to 300 and 
0 to 400 score, but by using the broader semicontinuous 0 to 
400 scale we are consistent with our previous work published 
on this and other cohorts.12,23–30 However, we did combine 3+ 
with 4+ and recalculate the H-scores. There was no difference 
between histologies with regard to PE, and there was no asso-
ciation with DFS or oS; in fact, there was less separation of 
the curves on the 0 to 300 scale compared to the 0 to 400.
The current study demonstrated a broad range of TS 
GCN by SISH, with increased values in a substantial propor-
tion of early-stage tumors. In 29% of the evaluable tumors, a 
mean GCN was three genes per nucleus, and in 7% the GCN 
was four or more. Thus, considering that in nontumor disomic 
tissue the typical average GCN is in the order of 1.8 genes 
per nucleus because of nuclear truncation,13 increased TS GCN 
seems frequent in NSCLC. Furthermore, we showed that ADCs 
tended to have lower levels of TS GCN, as might be expected 
given the results of some earlier studies using TS mRNA levels 
or PE.7,15 Importantly, however, in many SCCs there were also 
low levels of TS GCN, suggesting that a proportion of SCC 
patients may potentially benefit from pemetrexed therapy if 
low TS GCN is considered a predictive marker for sensitivity.
Gene amplification in cancer cells is one of the most 
frequent mechanisms leading to protein overexpression. other 
investigators have shown that amplification in the loci mapping 
to TS correlates with mRNA levels by quantitative reverse tran-
scription polymerase chain reaction and PE in a variety of tumor 
xenografts or colon cancer samples.10 our results for TS GCN 
are consistent with the previous mRNA studies, which demon-
strated increased mRNA expression in SCCs.7,17 Closer analysis 
of data from Ceppi et al.7 shows that although TS expression 
was generally higher in SCCs, there were still a proportion of 
SCCs with low mRNA expression and negative TS immunohis-
tochemical staining. In another study including stage-I resected 
NSCLC,s the median TS mRNA expression in SCC was twice 
that of ADC.15 In the latter study the range of expression accord-
ing to histology was not given, and therefore the proportion of 
SCCs with low mRNA expression levels is unknown.
In the present study, TS GCN either divided by the 
median cutoff point or considered as a continuous variable 
was not found to be prognostic for DFS or oS in the entire 
population of early-stage NSCLC patients. Furthermore, in 
patients with SCCs increased TS GCN had a tendency to asso-
ciate with increased survival, whereas this was not the case in 
the subset of ADCs and in other histologies. However, as these 
results were not statistically significant, it is unclear whether 
this trend occurred by chance or reflects a true biological rela-
tionship that might be verified in a larger sample size.
Aberrations in TS GCN are thought to result in gene 
overexpression and resistance to drugs that target TS. TS 
amplification, as determined by qPCR, was observed in lung 
cancer cell lines with acquired resistance to pemetrexed but 
not in the parental sensitive cell lines.8 Likewise, intrinsic 
resistance to pemetrexed in NSCLC cell lines correlated with 
increased TS gene expression.8,32 In freshly explanted tumor 
cells from multiple cancer types including lung, low levels of 
TS mRNA expression significantly correlated with sensitivity 
to pemetrexed.33 Single nucleotide polymorphism array assays 
and gene-dosage analysis in seven lung cancer and 20 other 
cancer xenografts showed that gains in the 18p11.32 locus 
mappings to TS correlate with increased resistance to pyrim-
idine analog-based drugs.10 These drugs target TS but via a 
mechanism different from pemetrexed. In a clinical study 
examining neoadjuvant gemcitabine plus pemetrexed, tumors 
with low TS mRNA expression were more sensitive to chemo-
therapy.9 Taken together, these results suggest that increased 
TS GCN in tumors may be involved in resistance mechanisms 
to TS-targeting drugs.
In the current study, a number of specimens were not 
evaluable for TS GCN because of insufficient signals. one 
of the reasons for failure to determine GCN includes nuclear 
truncation, which results in signal loss during the sectioning 
process. Another reason may be that our specimens, like many 
reported in the literature, were collected over several years and 
inevitably were fixed under variable conditions. This might 
have deleterious effects on the assay, even though substantial 
optimization was done before performing the experiment. 
Fixative or other processing conditions might have resulted 
in variable denaturation of the genomic DNA and thus affect 
hybridization efficiency. Necrotic tissue, which is unsuitable 
for hybridization because of degraded DNA, was intention-
ally avoided during construction of the TMA. However, some 
contamination with necrotic tissue, which is typical for lung 
tumors, cannot be fully prevented.
FIGURE 7. Dot plot showing the correlation between TS 
protein expression, represented by the H-score, and TS 
gene copy number. TS, thymidylate synthase.
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When the relationship between TS PE and GCN was 
examined, there was a significant correlation between the TS 
H-score and GCN, and the correlation increased substantially 
when the only patient with very high GCN was excluded 
from the analysis. our data shows that there are a number of 
patients with normal (disomic) GCN that have high to very 
high PE, suggesting that the increase in PE in these partic-
ular patients may be because of a mechanism other than an 
increase in GCN. Less common, but still observed, are those 
tumors with increased GCN (3) but modest PE, suggesting 
that in some instances PE may be regulated by mechanisms 
in addition to GCN. These data are highly consistent with 
our other published data comparing GCN and PE for addi-
tional genes, for example, epidermal growth factor receptor,27 
hepatocyte growth factor receptor,30 and insulin-like growth 
factor 1 receptor12 in NSCLC, and IGF1R24 in small cell lung 
cancer. In these previous studies, the results were similar in 
that some cases had normal GCN but elevated PE and a few 
cases had increased GCN but low PE.
In conclusion, our study showed that TS PE and GCN 
vary widely in NSCLC and that there is a significant correlation 
between PE and GCN. We observed no association of TS PE 
with histology or prognosis. TS GCN is frequently increased in 
surgically resected primary NSCLCs and differs by histology, 
with low GCN in most ADCs and a large variability of GCN 
in SCCs. We did not find any significant association between 
TS GCN and outcome. However, a broad range of TS GCN, 
particularly in SCCs, raises some questions not addressed in 
the phase-III studies that evaluated pemetrexed as first-line and 
maintenance therapy. Future prospective studies should address 
the question of potential benefit from pemetrexed therapy in a 
subset of SCC patients with low TS protein levels or low GCN 
because only then can one definitively determine the suitability 
of PE and/or GCN for predicting response and/or outcome to 
pemetrexed therapy. We also demonstrated that a new assay 
method for TS GCN assessment i.e., TS SISH, could easily be 
applied to the clinical setting. The potential predictive value of 
this assay for pemetrexed therapy warrants further validation.
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